142337-95-9

Basic information

• Product Name: Pyridine, 3-bromo-5-ethyl- (9CI)
• Synonyms: Pyridine, 3-bromo-5-ethyl- (9CI);3-BROMO-5-ETHYLPYRIDINE;Pyridine,3-bromo-5-ethyl-
• CAS NO: 142337-95-9
• Molecular Formula: C7H8BrN
• Molecular Weight: 186.04912
• EINECS: 147-856-9
• Product Categories: PYRIDINE;Halides;Pyridines;Heterocycle-Pyridine series
• Mol File: 142337-95-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 220.084oC at 760 mmHg
• Flash Point: 86.904oC
• Appearance: /
• Density: 1.413g/cm3
• Vapor Pressure: 0.171mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 3.22±0.20(Predicted)
• CAS DataBase Reference: Pyridine, 3-bromo-5-ethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-bromo-5-ethyl- (9CI)(142337-95-9)
• EPA Substance Registry System: Pyridine, 3-bromo-5-ethyl- (9CI)(142337-95-9)

Safety Data

• Hazardous Substances Data: 142337-95-9(Hazardous Substances Data)

Usage

General Description

Pyridine, 3-bromo-5-ethyl- (9CI) is a chemical compound part of the pyridine family, characterized by a six-membered ring structure that contains nitrogen in one of its carbon atoms. The term "(9CI)" signifies its registry number in the Chemical Index (CI). The term "3-bromo-5-ethyl-" denotes its structure and position of chemical groups, which include a bromine atom at the third position and an ethyl group at the fifth position on the pyridine ring. Pyridine, 3-bromo-5-ethyl- (9CI), like other members of the pyridine family, exhibits aromatic characteristics similar to those of benzene but it also has the ability to act as a base due to the nitrogen atom in its ring. It's mostly used in the chemical industry and scientific research for various synthesis processes.

InChI:InChI=1/C7H8BrN/c1-2-6-3-7(8)5-9-4-6/h3-5H,2H2,1H3

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 4433-63-0 Ethyl boronic acid 
• 38940-62-4 3-acetyl-5-bromopyridine 
• 536-78-7 3-ethylpyridine 

Downstream Products

• 98664-63-2 3-ethyl-5-formylpyridine 

Relevant articles and documents

Studies on the Nucleophilic Addition to 3,5-Disubstituted Pyridinium Salts

The reactivity of pyridinium salts 2 towards nucleophiles has been studied.The interaction with enolates derived from esters 1 gave only trace amounts of the expected compounds 3.Irreversible-type additions, however, allowed the preparation of indolyldihydropyridines 8 and 9 with high yields.Reaction of organometallic 10 with salt 2c, followed by acidic cyclization, afforded tetracycle 12.

INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).